HUP0400851A3 - Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists ii, process for their preparation and pharmaceutical compositions containing them - Google Patents

Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists ii, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
HUP0400851A3
HUP0400851A3 HU0400851A HUP0400851A HUP0400851A3 HU P0400851 A3 HUP0400851 A3 HU P0400851A3 HU 0400851 A HU0400851 A HU 0400851A HU P0400851 A HUP0400851 A HU P0400851A HU P0400851 A3 HUP0400851 A3 HU P0400851A3
Authority
HU
Hungary
Prior art keywords
diazepin
benzo
dihydro
derivatives
preparation
Prior art date
Application number
HU0400851A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HUP0400851A2 publication Critical patent/HUP0400851A2/hu
Publication of HUP0400851A3 publication Critical patent/HUP0400851A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU0400851A 2001-04-12 2002-04-02 Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists ii, process for their preparation and pharmaceutical compositions containing them HUP0400851A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109125 2001-04-12
PCT/EP2002/003644 WO2002083652A1 (en) 2001-04-12 2002-04-02 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II

Publications (2)

Publication Number Publication Date
HUP0400851A2 HUP0400851A2 (hu) 2004-07-28
HUP0400851A3 true HUP0400851A3 (en) 2010-03-29

Family

ID=8177126

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400851A HUP0400851A3 (en) 2001-04-12 2002-04-02 Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists ii, process for their preparation and pharmaceutical compositions containing them

Country Status (37)

Country Link
US (1) US6544985B2 (cg-RX-API-DMAC7.html)
EP (1) EP1379511B1 (cg-RX-API-DMAC7.html)
JP (1) JP4071115B2 (cg-RX-API-DMAC7.html)
KR (1) KR100566171B1 (cg-RX-API-DMAC7.html)
CN (1) CN1264825C (cg-RX-API-DMAC7.html)
AR (1) AR035816A1 (cg-RX-API-DMAC7.html)
AT (1) ATE299868T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002312788B2 (cg-RX-API-DMAC7.html)
BG (1) BG108254A (cg-RX-API-DMAC7.html)
BR (1) BR0208891A (cg-RX-API-DMAC7.html)
CA (1) CA2442557C (cg-RX-API-DMAC7.html)
CZ (1) CZ20033003A3 (cg-RX-API-DMAC7.html)
DE (1) DE60205100T2 (cg-RX-API-DMAC7.html)
DK (1) DK1379511T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP034797A (cg-RX-API-DMAC7.html)
ES (1) ES2246012T3 (cg-RX-API-DMAC7.html)
GT (1) GT200200073A (cg-RX-API-DMAC7.html)
HR (1) HRP20030792A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0400851A3 (cg-RX-API-DMAC7.html)
IL (2) IL157873A0 (cg-RX-API-DMAC7.html)
JO (1) JO2285B1 (cg-RX-API-DMAC7.html)
MA (1) MA27012A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03009311A (cg-RX-API-DMAC7.html)
MY (1) MY140271A (cg-RX-API-DMAC7.html)
NO (1) NO20034576L (cg-RX-API-DMAC7.html)
NZ (1) NZ528315A (cg-RX-API-DMAC7.html)
PA (1) PA8543301A1 (cg-RX-API-DMAC7.html)
PE (1) PE20021041A1 (cg-RX-API-DMAC7.html)
PL (1) PL367064A1 (cg-RX-API-DMAC7.html)
PT (1) PT1379511E (cg-RX-API-DMAC7.html)
RU (1) RU2263112C2 (cg-RX-API-DMAC7.html)
SI (1) SI1379511T1 (cg-RX-API-DMAC7.html)
SK (1) SK13682003A3 (cg-RX-API-DMAC7.html)
UY (1) UY27258A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002083652A1 (cg-RX-API-DMAC7.html)
YU (1) YU79003A (cg-RX-API-DMAC7.html)
ZA (1) ZA200307243B (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203294A3 (en) * 1999-10-15 2003-03-28 Hoffmann La Roche Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
SI1459765T1 (sl) * 2001-12-27 2009-02-28 Taisho Pharmaceutical Co Ltd Derivati 6-florobiciklo 3.1.0 heksana
EP1925614A1 (en) * 2002-03-28 2008-05-28 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
DK1490344T3 (da) 2002-03-28 2008-06-16 Wisys Technology Found Inc Anxiolytiske midler med reducerede sedative og ataktiske bivirkninger
ATE374030T1 (de) * 2003-07-25 2007-10-15 Hoffmann La Roche Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
DE602005004287T2 (de) * 2004-06-21 2008-12-24 F. Hoffmann-La Roche Ag Pyrrazolopyrimidinderivate
EP1851225B1 (en) * 2005-02-11 2011-06-15 F. Hoffmann-La Roche AG Pyrazolo-pyrimidine derivatives as mglur2 antagonists
MX2007011483A (es) 2005-03-23 2007-10-12 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de glutamato metabotropico 2.
EP1904481B1 (en) 2005-06-23 2016-02-17 Array Biopharma, Inc. Process for preparing benzimidazole compounds
AU2006298829B2 (en) 2005-09-27 2011-03-03 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists
GB0600228D0 (en) * 2006-01-06 2006-02-15 Fermentas Uab Inactivation method
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200808751A (en) * 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
MX2009002538A (es) 2006-09-20 2009-03-20 Hoffmann La Roche Derivados de 4-oxo-2,3,4,5-tetrahidro-benzo[b][1,4]diazepina.
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
KR101151993B1 (ko) 2007-04-19 2012-06-01 에프. 호프만-라 로슈 아게 다이하이드로-벤조[b][1,4]다이아제핀-2-온 설폰아미드 유도체
WO2009033702A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
EP2203439B1 (en) 2007-09-14 2011-01-26 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
EP2205565B1 (en) * 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
EP2373649B1 (en) 2008-11-28 2013-01-23 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010130424A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,3-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
EP2593447B1 (de) 2010-07-15 2016-08-17 Bayer Intellectual Property GmbH 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CA2834548C (en) 2011-04-28 2021-06-01 The Broad Institute, Inc. Inhibitors of histone deacetylase
JP5790195B2 (ja) * 2011-06-22 2015-10-07 セントラル硝子株式会社 ピラゾール化合物の製造方法
WO2013033246A2 (en) 2011-08-29 2013-03-07 Braincells, Inc. Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
KR20150070187A (ko) 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 mglu2/3 길항제
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
ES2929906T3 (es) 2012-12-28 2022-12-02 Crystalgenomics Inc Derivado de 2,3-dihidro-isoindol-1-ona como supresor de cinasa BTK, y composición farmacéutica que lo incluye
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
NZ724250A (en) 2014-03-07 2022-02-25 Biocryst Pharm Inc Human plasma kallikrein inhibitors
EP3134089A2 (en) 2014-04-23 2017-03-01 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of intellectual disabilities
US9969726B2 (en) 2014-06-10 2018-05-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof
CN108727345B (zh) * 2017-04-25 2023-06-27 广东东阳光药业有限公司 一种咪唑环中间体的制备方法
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CN108586447B (zh) * 2018-01-19 2021-01-29 中国人民解放军第四军医大学 一种苯二氮杂卓化合物及其制备方法和应用
MY209362A (en) * 2019-06-06 2025-07-03 Arcus Biosciences Inc Processes for preparing aminopyrimidine compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU224435B1 (hu) * 1995-02-09 2005-10-28 EGIS Gyógyszergyár Rt. Benzodiazepin-származékok, eljárás előállításukra, alkalmazásukra és ezeket tartalmazó gyógyászati készítmények
SK283859B6 (sk) * 1995-02-09 2004-03-02 Egis Gy�Gyszergy�R Rt. 1-[2'-(Substituovaný)vinyl]-5H-2,3-benzodiazepínové deriváty, spôsob ich prípravy a medziprodukty na ich prípravu, liečivá ich obsahujúce a ich použitie
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
RU2259360C2 (ru) * 1999-10-15 2005-08-27 Ф.Хоффманн-Ля Рош Аг Производные бензодиазепина и лекарственное средство, их содержащее
HUP0203294A3 (en) * 1999-10-15 2003-03-28 Hoffmann La Roche Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use

Also Published As

Publication number Publication date
ZA200307243B (en) 2004-12-16
IL157873A0 (en) 2004-03-28
PL367064A1 (en) 2005-02-21
YU79003A (sh) 2006-05-25
WO2002083652A1 (en) 2002-10-24
HUP0400851A2 (hu) 2004-07-28
DK1379511T3 (da) 2005-11-07
SK13682003A3 (sk) 2004-07-07
HK1068888A1 (en) 2005-05-06
CN1535266A (zh) 2004-10-06
PE20021041A1 (es) 2002-11-19
HRP20030792A2 (en) 2005-10-31
DE60205100T2 (de) 2006-06-01
KR20030087076A (ko) 2003-11-12
ECSP034797A (es) 2003-12-01
RU2003130637A (ru) 2005-04-10
GT200200073A (es) 2002-11-07
UY27258A1 (es) 2002-10-31
ES2246012T3 (es) 2006-02-01
AU2002312788B2 (en) 2005-11-10
MA27012A1 (fr) 2004-12-20
IL157873A (en) 2008-11-26
NO20034576L (no) 2003-11-12
US6544985B2 (en) 2003-04-08
SI1379511T1 (en) 2005-10-31
EP1379511B1 (en) 2005-07-20
PT1379511E (pt) 2005-10-31
CZ20033003A3 (cs) 2004-05-12
MY140271A (en) 2009-12-31
NO20034576D0 (no) 2003-10-10
CA2442557A1 (en) 2002-10-24
AR035816A1 (es) 2004-07-14
BR0208891A (pt) 2004-04-20
EP1379511A1 (en) 2004-01-14
KR100566171B1 (ko) 2006-03-29
JP2004529925A (ja) 2004-09-30
CN1264825C (zh) 2006-07-19
PA8543301A1 (es) 2003-01-24
US20020193367A1 (en) 2002-12-19
BG108254A (bg) 2004-09-30
CA2442557C (en) 2008-12-23
JO2285B1 (en) 2005-09-12
ATE299868T1 (de) 2005-08-15
JP4071115B2 (ja) 2008-04-02
MXPA03009311A (es) 2004-02-12
DE60205100D1 (de) 2005-08-25
NZ528315A (en) 2005-04-29
RU2263112C2 (ru) 2005-10-27

Similar Documents

Publication Publication Date Title
HUP0400851A3 (en) Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists ii, process for their preparation and pharmaceutical compositions containing them
HUP0400991A3 (en) Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i, process for their preparation and pharmaceutical compositions containing them
HUP0402026A3 (en) 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0203294A3 (en) Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203142A3 (en) Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0203902A3 (en) Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
HUP0203548A3 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0204245A3 (en) Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0300618A3 (en) Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0203316A3 (en) Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203052A3 (en) Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0300207A3 (en) 1,2,3,4-tetrahydroisquinoline derivatives, pharmaceutical compositions containing them and their preparation processes
HUP0201122A3 (en) Pyrimidinone compounds, process for their preparation and pharmaceutical compositions containing them
HUP0203836A3 (en) 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use
HUP0202731A3 (en) O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0105108A3 (en) Amide compounds, process for their preparation and pharmaceutical compositions containing them
HUP0201516A3 (en) 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0201753A3 (en) Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203140A3 (en) Bicyclic imidazo-5-yl-amine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0201402A3 (en) Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
HUP0203184A3 (en) Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203526A3 (en) Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0100489A3 (en) New piperidine-4-sulphonamide compounds, process for their preparation and pharmaceutical compositions containing them
HUP0201315A3 (en) 4-phenyl-pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished